125 related articles for article (PubMed ID: 12925107)
21. Pharmacokinetics and metabolism of single oral doses of trovafloxacin.
Vincent J; Teng R; Dalvie DK; Friedman HL
Am J Surg; 1998 Dec; 176(6A Suppl):8S-13S. PubMed ID: 9935250
[TBL] [Abstract][Full Text] [Related]
22. Pharmacokinetics and safety of trovafloxacin in healthy male volunteers following administration of single intravenous doses of the prodrug, alatrofloxacin.
Vincent J; Venitz J; Teng R; Baris BA; Willavize SA; Polzer RJ; Friedman HL
J Antimicrob Chemother; 1997 Jun; 39 Suppl B():75-80. PubMed ID: 9222074
[TBL] [Abstract][Full Text] [Related]
23. Activity of trovafloxacin (CP-99,219) against Legionella isolates: in vitro activity, intracellular accumulation and killing in macrophages, and pharmacokinetics and treatment of guinea pigs with L. pneumophila pneumonia.
Edelstein PH; Edelstein MA; Ren J; Polzer R; Gladue RP
Antimicrob Agents Chemother; 1996 Feb; 40(2):314-19. PubMed ID: 8834872
[TBL] [Abstract][Full Text] [Related]
24. In-vitro activity of trovafloxacin against sensitive and resistant aerobic bacteria using the standard microdilution broth method and Etest.
Dembry LM; Farrel PA; Orcutt DR; Gerrity LA; Andriole VT
J Antimicrob Chemother; 1997 Jun; 39 Suppl B():35-42. PubMed ID: 9222068
[TBL] [Abstract][Full Text] [Related]
25. Pharmacodynamics of trovafloxacin in a mouse model of cephalosporin-resistant Streptococcus pneumoniae pneumonia.
Ng W; Lutsar I; Wubbel L; Ghaffar F; Jafri H; McCracken GH; Friedland IR
J Antimicrob Chemother; 1999 Jun; 43(6):811-6. PubMed ID: 10404320
[TBL] [Abstract][Full Text] [Related]
26. Comparison of ex-vivo serum bactericidal activity of cefepime, ceftazidime and cloxacillin against Staphylococcus aureus.
Dan M; Asherov J; Poch F
Diagn Microbiol Infect Dis; 1999 Jan; 33(1):39-42. PubMed ID: 9990474
[TBL] [Abstract][Full Text] [Related]
27. Efficacy of trovafloxacin in an in vitro pharmacodynamic simulation of an intraabdominal infection.
Alou L; Anta ML; Del Potro MG; Fuentes F; Balcabao IP; Gomez-Lus ML; Prieto J
Int J Antimicrob Agents; 1999 Jul; 12(2):135-9. PubMed ID: 10418758
[TBL] [Abstract][Full Text] [Related]
28. Urinary concentrations and bactericidal activities of newer fluoroquinolones in healthy volunteers.
Stein GE; Schooley S
Int J Antimicrob Agents; 2004 Aug; 24(2):168-72. PubMed ID: 15288316
[TBL] [Abstract][Full Text] [Related]
29. Hepatobiliary elimination of trovafloxacin and metabolites following single oral doses in healthy volunteers.
Melnik G; Schwesinger WH; Teng R; Dogolo LC; Vincent J
Eur J Clin Microbiol Infect Dis; 1998 Jun; 17(6):424-6. PubMed ID: 9758286
[TBL] [Abstract][Full Text] [Related]
30. In vitro activity of trovafloxacin against ciprofloxacin-susceptible and -resistant clinical bacterial isolates and assessment of the trovafloxacin disk test.
Fuchs PC; Barry AL; Brown SD
Diagn Microbiol Infect Dis; 1999 Jan; 33(1):33-8. PubMed ID: 9990473
[TBL] [Abstract][Full Text] [Related]
31. Influence of subinhibitory concentrations of cephalosporins on the serum sensitivity of Pseudomonas aeruginosa.
Darveau RP; Cunningham MD
J Infect Dis; 1990 Oct; 162(4):914-21. PubMed ID: 2119402
[TBL] [Abstract][Full Text] [Related]
32. In vitro activities of ceftobiprole combined with amikacin or levofloxacin against Pseudomonas aeruginosa: evidence of a synergistic effect using time-kill methodology.
Kresken M; Körber-Irrgang B; Läuffer J; Decker-Burgard S; Davies T
Int J Antimicrob Agents; 2011 Jul; 38(1):70-5. PubMed ID: 21514795
[TBL] [Abstract][Full Text] [Related]
33. In vitro activity of gemifloxacin against a broad range of recent clinical isolates from the USA.
McCloskey L; Moore T; Niconovich N; Donald B; Broskey J; Jakielaszek C; Rittenhouse S; Coleman K
J Antimicrob Chemother; 2000 Apr; 45 Suppl 1():13-21. PubMed ID: 10824027
[TBL] [Abstract][Full Text] [Related]
34. Single- and multiple-dose administration, dosing regimens, and pharmacokinetics of trovafloxacin and alatrofloxacin in humans.
Vincent J; Dogolo L; Baris BA; Willavize SA; Teng R
Eur J Clin Microbiol Infect Dis; 1998 Jun; 17(6):427-30. PubMed ID: 9758287
[TBL] [Abstract][Full Text] [Related]
35. Pharmacodynamic studies of trovafloxacin and grepafloxacin in vitro against Gram-positive and Gram-negative bacteria.
Odenholt I; Cars T; Lowdin E
J Antimicrob Chemother; 2000 Jul; 46(1):35-43. PubMed ID: 10882686
[TBL] [Abstract][Full Text] [Related]
36. Geographic variations in activity of broad-spectrum beta-lactams against Pseudomonas aeruginosa: summary of the worldwide SENTRY Antimicrobial Surveillance Program (1997-2000).
Jones RN; Kirby JT; Beach ML; Biedenbach DJ; Pfaller MA
Diagn Microbiol Infect Dis; 2002 Jul; 43(3):239-43. PubMed ID: 12106958
[TBL] [Abstract][Full Text] [Related]
37. Comparison of five beta-lactam antibiotics against common nosocomial pathogens using the time above MIC at different creatinine clearances.
Kays MB
Pharmacotherapy; 1999 Dec; 19(12):1392-9. PubMed ID: 10600088
[TBL] [Abstract][Full Text] [Related]
38. Activity of clinafloxacin, trovafloxacin, quinupristin/dalfopristin, and other antimicrobial agents versus Staphylococcus aureus isolates with reduced susceptibility to vancomycin.
Cohen MA; Huband MD
Diagn Microbiol Infect Dis; 1999 Jan; 33(1):43-6. PubMed ID: 9990475
[TBL] [Abstract][Full Text] [Related]
39. Urine bactericidal activity after administration of gemifloxacin and trovafloxacin single doses in a phase I study.
García-Calvo G; Parra A; Ponte C; Soriano F; Giménez MJ; Aguilar L
Int J Antimicrob Agents; 2002 Dec; 20(6):477-80. PubMed ID: 12458147
[No Abstract] [Full Text] [Related]
40. Pharmacokinetics and pharmacodynamics of cefepime administered by intermittent and continuous infusion.
Burgess DS; Hastings RW; Hardin TC
Clin Ther; 2000 Jan; 22(1):66-75. PubMed ID: 10688391
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
